Acadia Pharmaceuticals Inc. (ACAD) Stock Price & Analysis

Acadia Pharmaceuticals Inc. (ACAD) is trading at USD 20.76, up 2.14% today, as of October 29, 2026 at 19:40 UTC (US market open; quotes may be delayed), according to Nexqual market data.

ACAD last closed at USD 20.32; today's session has ranged USD 20.5–20.77 on volume of 798,570 shares. Market capitalization is $3.58B, with a 52-week range of USD 18.39–30.96 (NMS). Source: Nexqual, retrieved October 29, 2026 at 19:40 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ACAD.md

Key facts (ACAD)

• Last four reported quarters (through Jun 30, 2026): revenue $1.14B, net income $380M (33.4% margin), free cash flow $146M (SEC filings).
• Valuation: P/E 9.4x (avg 12.6x at the last 2 fiscal year-ends).
• Insider open-market sales, last ~7 months: 6 Form 4 filings, $1.5M; 1 not under a Rule 10b5-1 plan ($114K); 0 by opportunistic insiders, 5 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.15 on a 1–5 scale) (20 analysts), mean target USD 30.53 (range 16–37).
• Total return with dividends: 1Y -7.9% vs S&P 500 +12.9%; 5Y +15.6% vs S&P 500 +78.8%.
• Next earnings: 2026-11-04, EPS estimate USD 0.18, revenue estimate $333M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ACAD)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ACAD)

P/E 9.4x · P/S 3.1x · P/FCF 24.5x · P/B 2.7x · FCF yield 4.07% · Earnings yield 10.64%

P/E at fiscal year-ends: Dec 2025 11.6x, Dec 2024 13.5x.

Insider sales (SEC Form 4, open-market, last ~7 months) (ACAD)

5 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ACAD)

Consensus Buy (mean 2.15 on a 1–5 scale), 20 analysts; mean target USD 30.53 (low 16, high 37).

Rating changes, last 120 days:

Total return (dividends reinvested) (ACAD)

ACAD earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ACAD recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ACAD revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

ACAD suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name ACAD in their SEC reports

ACAD analyst estimates and revisions

ACAD options: expected move

Options price a move of about ±9.6% (±$1.95) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±4.6% on average.

30-day implied volatility 41.9% vs 53.9% realized over the last 30 trading days. Put/call ratio (volume) 4.08. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 19:40 UTC)

Technical Analysis (ACAD)

Nexqual's technical model rates ACAD "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of October 29, 2026 at 19:40 UTC.

Analyst Ratings (ACAD)

Wall Street analysts rate ACAD "Buy" based on 20 analysts, with a mean price target of USD 30.53 (range USD 16–37), per Nexqual as of October 29, 2026 at 19:40 UTC.

Earnings (ACAD)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 19:40 UTC.

Financials & Fundamentals (ACAD)

Source: Nexqual, October 29, 2026 at 19:40 UTC.

Financial Health Score (ACAD)

Nexqual rates Acadia Pharmaceuticals Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 19:40 UTC.

Ownership (ACAD)

Source: Nexqual, October 29, 2026 at 19:40 UTC.

Leadership (ACAD)

Acadia Pharmaceuticals Inc. is led by Catherine E. Owen Adams, CEO & Director, per Nexqual as of October 29, 2026 at 19:40 UTC.

Major Backers & Investors (ACAD)

Notable institutional backers of Acadia Pharmaceuticals Inc. include Baker Bros. Advisors, LP, RTW Investments LP, Palo Alto Investors Lp, according to Nexqual as of October 29, 2026 at 19:40 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 19:40 UTC.

From Acadia Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Before commencing clinical investigations in humans, we or our collaborators must submit an Investigational New Drug Application (IND), to the FDA.
• The data and information are submitted to the FDA in the form of a New Drug Application (NDA), which must be accompanied by payment of a significant user fee unless a waiver or exemption applies.
• Our patent applications claim proprietary technology, including chemical synthetic or manufacturing methods, drug assays, novel compounds, compositions, formulations and methods of treatment.

Partnerships

• In July 2023, we expanded the 2018 licensing agreement with Neuren to acquire rights to trofinetide outside of North America as well as global rights to Neuren's development candidate NNZ-2591 in Rett syndrome and Fragile X syndrome.
• In November 2024, we entered into an exclusive worldwide license agreement with Saniona A/S (Saniona) for the development and commercialization of ACP-711 (formerly SAN711).

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject, directly and indirectly, to federal, state and foreign healthcare laws and regulations, including healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
• We could face liability if a regulatory authority determines that we are promoting our products for any "off-label" uses.
• We are subject to stringent regulation in connection with the marketing of our products, which could delay the development, approval and commercialization of our products.
• We may expend significant resources or fundamentally change our business activities and practices (including our clinical trials) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 19:40 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt